“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses

Author(s): Dimitri P. Mikhailidis, Moses Elisaf, Manfredi Rizzo, Kaspar Berneis, Bruce Griffin, Alberto Zambon, Vasilios Athyros, Jacqueline de Graaf, Winfried Marz, Klaus G. Parhofer, Giovam Battista Rini, Giatgen A. Spinas, Gerald H. Tomkin, Alexandros D. Tselepis, Anthony S. Wierzbicki, Karl Winkler, Matilda Florentin, Evangelos Liberopoulos

Journal Name: Current Vascular Pharmacology

Volume 9 , Issue 5 , 2011

Become EABM
Become Reviewer
Call for Editor


Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density lipoproteins (LDL) subclasses. We sub-divided our Statement in 2 sections: section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drugs and lifestlyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.

Keywords: LDL, subclasses, atherosclerosis, cardiovascular risk, statement, hypertriglyceridaemia, coronary heart disease, cardiovascular disease, apolipoprotein, chylomicrons

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [533 - 571]
Pages: 39
DOI: 10.2174/157016111796642661
Price: $65

Article Metrics

PDF: 28